Clinical Study
Rivaroxaban Transfer into Human Milk After Childbirth
Right after a female gives birth to a baby the female could need to take a blood thinner medication for their health. The study will test to see if giving a female right after the birth of their baby a low dose of rivaroxaban (a common blood thinner) medication by mouth passes into human milk. The information will help to better understand if rivaroxaban can be used by the female when breastfeeding a baby. Being in the study requires females who are NOT or will STOP breastfeeding or pumping breastmilk to take two low doses of the rivaroxaban (24 hours apart) by mouth. Then the breastmilk and blood samples will be collected. The study will test the samples to see if rivaroxaban passes into human milk, and if so, at what amount. Participants will be paid for being in the study.
For more information contact:
Salman Yakub
salman.yakub@hsc.utah.edu
8016467991
IRB#: IRB_00167245
| PI: Ann Bruno
| Department: MATERNAL-FETAL MEDICINE DIV
| Approval Date: 2023-08-30 06:00:00
Specialties: OB/Gyn, General
Who can participate?
Gender: Female Only
Age: Over 18 years old
Volunteers: Healthy Volunteers
Location: In Person
Inclusion Criteria:
- Ages 18 years and older
- Delivering a baby at the University of Utah or other facilities
- NOT breastfeeding or will STOP breastfeeding their baby
- Able to attend in person at the study clinic
Exclusion Criteria:
- Specific medical conditions such as liver disease, diabetes
- Taking other medication that affects the medication rivaroxaban
Will I be paid for my time?
Yes